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The progress in reperfusion therapy dictated the necessity for developing new tools and procedures for adjacent/additional
therapy of acute cardiovascular disorders. The adjacent therapy is targeted on the damage of the microcirculation, leading to
the unfavorable prognosis for the patients. The no-reﬂow phenomenon holds special place in the multifactorial etiology of the
microcirculation disorders, oﬀering a new challenge in treating the patients associated with ST-segment elevation on ECG at
myocardialinfarction.Oneofthenumerouscausesofno-reﬂow,theinﬂuenceoftheendothelialglycocalyxofthemicrocirculation,
is analyzed. The results obtained in the studies of the endothelial glycocalyx ultrastructure are generalized, the eﬀe c tt h a tt h e
fragments of the glycocalyx glycosaminoglycans have on the function of the vascular wall is demonstrated. The trends in searching
for correlations between the thickness of the capillary glycocalyx and the cardiovascular disease risk are noted.
1.Introduction
The continuous improvement of the methods, tools, and
medications for reperfusion therapy is motivated by the
necessity to reduce the high morbidity and mortality rates
for cardiovascular disorders. Acute coronary syndrome is a
critical manifestation of ischemic heart disease. The onset of
this syndrome can lead to unstable angina pectoris attacks,
to the acute myocardial infarction (AMI), and to the sudden
cardiac death. The size of myocardial infarction serves as
the primary determinant of the prognosis for such patients.
The mortality rate over the ﬁrst six months in patients with
infarct size over 20% left ventricle was 2%, and increased
to 4.5%, when the lesion size was higher than 35% [1].
An understandable signiﬁcance of reduction in AMI size,
however, did not ﬁnd a reliable clinical conﬁrmation in the
studies [2–4]. The reason is that the reduction of AMI size
(although it has a signiﬁcant eﬀect on the prognosis in the
patientswiththelesionsizeof20%leftventricleandmore)is
achieved more often in the patients who have smaller lesions
(<20%leftventricle),thatis,inthepatientswhoalreadyhave
a favorable prognosis [5]. Therefore, a successful treatment
of severe cases is of especial importance for reducing
mortality rates in the patients with AMI. The contemporary
reperfusion therapy limits AMI sizes approximately by 50%
of ischemized area in half of the patients with AMI, leaving
outaquarterofthepatientswithmorethan75%ofthelesion
in the risk zone. This sets an objective of reducing the infarct
size from 75% of the lesion or higher down to less than 40%
[5]. In a quarter of the patients with AMI this goal could not
be accomplished by using the required reperfusion therapy
alone, and so an adjunctive (additional) therapy is necessary
[6]; the purpose of this adjacent (adjunctive) therapy is to
reduce the infarction damage of the left ventricle down to
20% or less [5].
2. Necessity for Adjacent Therapy in
TreatingDisordersof Microcirculation/
Tissue Perfusion
One of the reasons for severe progression of AMI is the
damage of the tissue perfusion/microcirculation [7]. The
positron emission tomography shows that some of the2 Biochemistry Research International
patients with AMI have reduced tissue perfusion caused
by the damage of the capillaries induced by ischemia and
reperfusion, even after the successful thrombolysis in the
infarct-related artery (patency rates reaching TIMI grade
3). As a result, the function of the left ventricle is not
restored, which leads to the unfavorable prognosis for these
patients.Thefunctionalrecoveryoftheaﬀectedmyocardium
was observed only when the patency of the obstructed
vessel and an adequate restoration of tissue permeability
were ensured [7]. An adjunctive therapy is required for
the functional restoration of the microvasculature [6]. The
necessity of additional therapeutic intervention for these
disorders in the case of complicated AMI was demonstrated
by using echocardiography, nuclear magnetic resonance,
Doppler scanning [8], angiography (employing semiquan-
titative classiﬁcation of microcirculatory perfusion levels)
[9], electrocardiography, by measuring plasma levels of the
myocardial proteins (creatine kinase MB, troponin T or I,
myoglobin) [10, 11], and using positron emission tomog-
raphy [12] .T h e s ed a t ah e l p e dt om o v ef r o mt h ec o n c e p to f
open artery to the achievement of the “optimal reperfusion,”
designed, aside from the reperfusion of an occluded artery,
to eliminate the dysfunction of microcirculation, improve
tissue perfusion, and reduce the “reperfusion” damage [13].
The current situation shows that the use of adjunctive ther-
apy in patients with acute cardiovascular disorders may have
various purposes [6, 13]. This review is primarily focused on
the problems associated with disorders of microcirculation.
3.Disturbancesof Microcirculation:
No-Reﬂow Phenomenon
Microcirculation is a part of blood circulation system. Oxy-
gen, nutrients, hormones, and metabolites are exchanged
between the circulating blood and the parenchymal cells
in the microcirculation bed. The microvessels are divided
by their anatomic characters and the direction of blood
ﬂow into arterioles, capillaries, and venules, the diameter of
which is thought to be less than 100 [14] or 200μm[ 15].
Arterioles, the thin branches of arteries, are the principal
resistance component of microcirculation. The venules serve
as a large reservoir of low pressure (capable to hold up to
75% total blood volume), through which the blood returns
into the heart. The main function of capillaries is to facilitate
the exchange of molecules between blood and tissues. An
adequate capillary circulation is a necessary prerequisite for
normal perfusion and organ functioning. Capillary patency
is the principal determinant of capillary tissue perfusion and
is characterized by the functional capillary density (FCD).
The latter is deﬁned as the number of functioning capillaries
(i.e., the capillaries with circulating erythrocytes) per tissue
area. The major distinctive feature of microcirculation is its
heterogeneity (in terms of blood ﬂow distribution, FCD,
expression of vasoactive products, etc.). The disorders of
themicrocirculationaresepsis,hypovolemicandcardiogenic
shock, and no-reﬂow phenomenon (the failure to restore
the microﬂow) [14, 16]. It is believed that in the case of
sepsis (associated with local hypoxia and organ dysfunction)
and cardiogenic shock (i.e., a response to the generalized
inﬂammation with compensatory redistribution of blood
volume/due to active venoconstriction/with reduction of the
peripheral vascular capacity), the disturbances of microcir-
culation occur irrespective of the systemic hemodynamic
changes, although in the latter case this conclusion is
disputed [14]. In the case of hypovolemic shock (caused,
e.g., by a signiﬁcant blood loss, and accompanied by pro-
nounced hypotension), the changes in microcirculation are,
at least, not completely independent from the hemodynamic
parameters. The hemodynamic parameters are correlated
with the “no-reﬂow” phenomenon [17, 18]. One of the def-
initions of the “no-reﬂow” phenomenon is incomplete and
nonuniﬁed reperfusion at the microcirculatory level, despite
an adequate reopening of the proximal artery after a period
of transient ischemia [19]. The cases of vascular damage of
the myocardium allow us to generalize the concept of no-
reﬂow as the state of myocardial tissue hypoperfusion with
the patency of epicardial coronary arteries [15, 18, 20]. Two
types of no-reﬂow are distinguished: “structural” no-reﬂow,
characterizedbyirreversibledamagetothecellsofthemicro-
circulation, and “functional” no-reﬂow, characterized by the
disturbance of microcirculation caused by vasoconstriction
and/or microembolization [21]. The latter can be caused
by the fragments of a lysed thrombus, destroyed atheroscle-
rotic plaque, aggregates of erythrocytes or leukocytes with
platelets, or by large platelets [15, 20, 22]. The high volu-
metric content of necrotic material in the plaque correlates
with the development of microembolization, determined by
the levels of the released seromarkers—creatine kinase and
troponin I [23]. The stenting causes less prominent release
of cardiac markers than does the atheroablative technology.
These interventions can be associated with “reperfusion”
no-reﬂow (which occurs after ischemia/reperfusion during
the treatment of AMI) and with “interventional” no-reﬂow
(associated with angioplasty without myocardial infarction
and without a prolonged ischemia prior to the procedure)
[15]. The duration of ischemia can have a signiﬁcant eﬀect
on speciﬁc manifestations of no-reﬂow. “Interventional” no-
reﬂow following a short period of ischemia (seconds or
minutes) is caused primarily by microvascular obstruction,
inﬂammatory response, or secondary ischemia. A prolonged
(hours) ischemia causes no-reﬂow due to “reperfusion”
(ischemia/reperfusion) injury, myocardial edema, endothe-
lial swelling, capillary embolism, vasospasm, or inﬂamma-
tory response [15]. The ﬁrst 2-3 hours of ischemia in
the case of AMI lead to myoﬁbrillar edema, followed (6-
7 hours of ischemia) by interstitial edema [24]. A more
prolonged ischemia leads to the reduction of edema, to the
destruction of microcirculation bed, and to the thinning
of the myocardial walls. The inhibition of δ-isoform of
protein kinase C by a fragment of its inhibitor, protein
δV1-1, performed on isolated hearts of transgenic mice
expressing δV1-1 and on AMI model in pigs reduces
the microcirculatory dysfunction, decreasing the no-reﬂow
phenomenon [25, 26]. The elevation in the levels of plasma
thromboxane A2 was observed in the patients with AMI
(with ST-segment elevation on ECG), following the primary
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thatthelevelofthromboxaneA2isanindependentpredictor
of the no-reﬂow phenomenon after the angioplasty, which
sets new goals for reducing of this complication. However,
the eﬀorts of pharmacologists and clinicians to achieve
the same results using adenosine, sodium nitroprusside,
nitroglycerine, nicorandil, verapamil, glycoprotein inhibitor
IIb/IIIa, and papaverine have not as yet produced any
tangible results [15, 26]. The multifactorial nature of the
no-reﬂow development is emphasized by the assumption
that the formation of ﬁbrin clots with reduced permeability
and increased resistance to ﬁbrinolysis can be aﬀected in
these conditions by the genetic data of the patient [27]. The
diversity of the available data and the lack of an eﬀective
approachtothetherapyofno-reﬂowphenomenonmakethis
goal the next challenge in treating the patients with AMI [20,
26]. The personalized management of no-reﬂow has been
proposed for clinical application on the basis of the assess-
ment of the prevailing mechanisms of no-reﬂow operating
in each patient [28]. Variable combinations of human no-
reﬂow causes include four pathogenetic components: distal
atherothrombotic embolization, ischemic and/or reperfu-
sion injury, susceptibility of coronary microcirculation to
damage. In order to understand the mechanism of this
pathology, we should know its components. The review
presented above shows that the investigators tend to neglect
the role of the carbohydrate coating of the microvessels,
which (due to the reduction of the eﬀective size of the
vascular lumen and due to the vessel walls coming closer
together and to the occlusion material) cannot be completely
uninvolved in the development of the microcirculation
disorders [29].
4.CarbohydrateCoatingof theVascularWall
The endothelial glycocalyx (EG) is an uneven “ﬂuﬀy”
polysaccharide coating over the vascular wall toward the
vessel lumen. This polysaccharide “fur” on the cell surface
is composed of proteoglycans and glycoproteins, attached to
the cell membrane and capable to bind blood constituents,
which can be important for the vascular function. The size of
the glycocalyx in the microvessels is 0.4-0.5μm, which is 10–
20% of the vascular volume [30]. The diameter of the cell-
freelayer in these vessels is over 20μm[ 31]. Itis believed that
the glycocalyx permeability is mediated by the hyaluronan,
and the glycocalyx volume is regulated by the proteoglycans
[32, 33]. The composition of glycosaminoglycans implies the
content of hyaluronan more than 40%, heparansulfate more
than 50%, and chondroitinsulfate/dermatansulfate around
10% [34]. These glycosaminoglycans (besides hyaluronan)
are linked covalently to core proteins [34–36]. They together
with glycosaminoglycans form the proteoglycans. Core
proteins are syndecans (number of subtypes is four) and
glypicans (number of subtypes is six). Syndecans are linked
ﬁrm to cell membrane via a membrane-spanning domain,
but glypicans are linked via a glycosylphosphatidylinositol
anchor. There are membrane proteoglycans (syndecans
of subtypes 1–4 and glypicans of subtypes 1–6), soluble
proteoglycans(perlecan,biglycan,andothers),andﬁvetypes
of glycosaminoglycan chains (heparin sulfate, chondroitin
sulfate, dermatan sulfate, keratan sulfate, hyaluronic acid).
These components consist of membrane-bound and asso-
ciated layers of glycocalyx. Composition and function of
endothelial glycocalyx are detailed in [34, 36]. It should be
noted that glycocalyx composition cannot be viewed as a
static object. There is a dynamic equilibrium between glyco-
calyx layer of soluble components and the ﬂowing blood. It
is possible to say the glycocalyx is an intricate self-renewing
3Dmeshofvariouspolysaccharidederivatives[34–36].EGis
therefore considered to be a protective layer on the vascular
wall providing defense against pathogens, a traﬃcm e s h w o r k
barrier for transendothelium transportation of molecules,
and a porous hydrodynamic partner in interaction with red
and white blood cells in the microcirculation.
The resistance of arterioles to the protein ﬂux through
their walls was found to be associated with the glycocalyx
inﬂuence [37]. The inﬂammation and the inﬂuence of
ischemia/reperfusion facilitate the breakdown of glycocalyx
in the venules and capillaries [38–40]. When microthrom-
boses in mice were induced by an infective stimulus
(lipopolysaccharide), the levels of von Willebrand factor
expression were increased in the venules, but not in the arte-
rioles [41]. The degradation of glycocalyx in the myocardial
capillariesresultsinarapiddevelopmentofmyocardialtissue
edema [42]. The treatment with hyaluronidase of hamster
capillary glycocalyx has shown that it is the pronounced
hyaluronandependent [30]. Hyaluronidase treatment was
associated with the reduction of the glycocalyx volume, the
increase of the volume of circulating plasma, the decrease
of FCD, and the elevation of hematocrit. These changes in
the glycocalyx lead to the alteration of the transendothelial
permeability, thereby causing the swelling of the endothelial
cells,whichis one of the regulatoryfactorsfor FCD [30].The
reduction of FCD shows how the worsening of the condition
of capillary glycocalyx can lead to the onset of the disease.
The properties of the microcirculation glycocalyx can medi-
ate the regulation of the blood transport function; these
properties have recently been reviewed [29]. In humans, the
evidence for shedding of EG during ischemia/reperfusion
procedures was demonstrated already also [43].
5. Glycocalyx Components for DrugTargeting
The possibility of using glycocalyx components in the
targeted drug delivery systems appears to be both interesting
and promising [44]. The exposure of chondroitinsulfate
proteoglycan in the subendothelial layer of the rabbit
arteries after its stenting causes binding of the positively
charged liposomes to this substance (along with cationic
lipid TRX-20 and prednisolon serving as the drug) and
the accumulation of such nanoparticles in the lesion area
[45]. This has resulted in a prominent reduction of the
neointima growth in the area of the stent. The treatment
of the aﬀected area with chondroitinase ABC prior to the
injectionofliposomespreventstheirbindinginthisarea.The
experiment conducted on subendothelial cells (from human
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TRX-20 liposomes to these cells, but not to the endothelial
cells [46]. The treatment of subendothelial cells (smooth
muscles and mesangial cells) with chondroitinase (but not
with heparinase) reduces their binding to the liposomes
studied, which proves the speciﬁcity of this interaction.
It should be noted that liposomes can measurably bind
to the endothelium, depending on the type of cationic
lipids and their concentration in the liposomes [47]. The
eﬀects of binding of various ligands (lipoproteins, proteins,
peptides, saccharide derivatives, etc.) to the components of
EG have recently been reviewed [29]. Erythrocyte-associated
tissue-type plasminogen activator (tPA) was proved to have
ap o t e n t i a lo fav e r ye ﬀective agent of cerebrovascular
thromboprophylaxis [48]. Biotinilated tPA and erythrocytes
are associated via streptavidin [49]. The use of this adduct
in mice with cerebral thrombosis results in thrombolysis,
generating a rapid and prolonged reperfusion, whereas no
eﬀect is observed when tPA itself is administered even in ten-
fold higher doses. Because of the coupling with erythrocytes,
tPA has a prolonged half-life period in the blood, the ability
to lyse fresh thrombi (rather than old hemostatic plugs), and
a reduced eﬃciency of inhibition by plasminogen activator
inhibitor of type I (PAI-1) [49]. The latter observation was
explained by the protection provided by the erythrocyte
glycocalyx preventing tPA from interacting with PAI-1,
which disappears when the erythrocytes are treated with a
mixture of neuraminidase, hyaluronidase, and heparinase
[50]. The erythrocyte glycocalyx does not prevent the
associatedtPAfrominteractingwithﬁbrinandplasminogen,
but protects it from glycation by glucose. Of course, the
similarity and diﬀerence of glycocalyx on leucocytes, ery-
throcytes, subendothelial cells to that on the endothelium
has to determine else. A protective eﬀect of glycocalyx is
thought to be associated with screening the interaction
centers on tPA provided by glycocalyx and with changes
in electrostatic interactions. In our opinion, such eﬀects
(binding of the cationic liposomes to chondroitinsulfate-,
but not to heparansulfate-proteoglycan [45], inhibition of
the associated tPA interaction with PAI-1, but not with ﬁbrin
and plasminogen [49], that occur in the space of speciﬁcally
positioned electrostatic charges) imply the presence of a
suitable charge distribution network in glycocalyx. The
orienting eﬀect of this network on the binding counter-
partner enables the detection of its suitability/unsuitability
for a productive interaction. The presence of this charge
distribution network can signify a speciﬁc ultrastructure
of the glycocalyx. The study of this network is currently
underway [29, 50].
6.The Study of GlycocalyxUltrastructure
The samples of microvascular (capillaries and venules)
glycocalyx from the frog endothelium prepared for electron
microscopy using various techniques (freezing and chemical
ﬁxation) have yielded similar results [51] .T h es i z eo f
glycocalyx in the normal microvessels was less than 0.2μm;
it was, however, observed that its in vivo size could be
much higher and could be reduced, when the samples
are prepared for electron microscopy. In the inﬂamed
microvessels, where inﬂammation was induced using “tem-
perature jump” technique, the glycocalyx changed its shape
to form protuberances on the cell surface (extensions,
depressions, and other irregularities) and increased in thick-
ness (0.3-0.4μm). Computerized autocorrection functions
and Fourier transformations reveal the ultrastructure of
EG in the microvessels. A structural quasiperiodicity of
the glycocalyx meshwork was detected along the horizontal
and vertical axes (the periodicity intervals are ∼20nm, the
diameter of ﬁbers is 10–12nm, and the distance between
the bases of quasihexagonal meshwork elements (Figure 1)
is approximately 100nm [51]). This structure is consistent
with the ﬁber matrix model that views the glycocalyx as
an extracellular molecular ﬁlter. A systematic variation in
the length of the side proteoglycan chains on the cell
surface (axial periodicity along the proteoglycan molecule),
and/or regulatory binding of plasma proteins (e.g., such
ones albumin and orosomucoid [36]) by highly charged side
chains of glycoproteins regularly positioned in the nodes
of the glycocalyx network can serve as regulatory forces
that mediate the transport through the glycocalyx (Figure 2)
[51]. A speciﬁc proﬁle of the electrostatic surface potential
formed by this network is likely to trigger the initiation of
recognition/binding oftheinteractioncounter-partner(with
as u ﬃciently complementary electrostatic surface potential)
or to ignore the unsuitable counter-partner. This could have
explained a targeted binding of the cationic liposomes to
chondroitinsulfate-, but not to heparansulfate-proteoglycan
[45, 46], as well as the inhibition by the erythrocyte
glycocalyx of tPA interaction with PAI-1, but not with ﬁbrin
and plasminogen [49, 50]. This question deﬁnitely warrants
further study.
The treatment of the blood cells, intended for scanning
electron microscopy, with 2.56M (15%) NaCl solution [52]
provides a very informative approach for studying this
problem. During this procedure, gel microenvironment is
formed around the cells (taken from the patient blood
with chronic lymphatic leukemia or myeloleukemia); this
microenvironment has a regular meshwork structure. The
cell diameter, including the swollen glycocalyx-gel around
the cell, is approximately 10–20μm. The meshwork periodic
structure (period of 100–150nm) of the tumor cells was
clearlyrevealedbyatomicforcemicroscopy[53].Areversible
increase in size of the cellular glycocalyx reaches three
orders of magnitude [52, 53] ,w h i c hm a k e st h i sa p p r o a c h
a very convenient technique for studying the structure of
glycocalyx.
At the same time, it is assumed [50] that the organization
of the glycocalyx ultrastructure (100nm topographic dis-
tances between the glycocalyx ﬁbers on the cellular surface,
Figure 1) is determined by the quasiregular architecture of
thesubmembranecytoskeleton.Itispossiblethattheinﬂam-
mation alters the glycocalyx by changing the structure of the
cytoskeleton, which in turn triggers the over-production of
the glycocalyx [51]. This change can be initiated as a result
of the eﬀect that the high ionic strength of the medium
has on the cytoskeleton of the tumor cells and/or as a
result of the increased swelling of the glycocalyx [52, 53].Biochemistry Research International 5
Figure 1: Reconstructed high-periodicity meshwork of the blood
leukocyte glycocalyx composed of individual natural nanopar-
ticles. The meshwork composition is projected onto a plane.
Electron microscopy: the bar corresponds to the minimum size
of the nanoparticle, which is 50nm under 15% NaCl electrolyte
concentration (hypertonic solution) or 3 nm under 0.9% NaCl
electrolyteconcentration(isotonicsolution)(GolovanovMV,Bauer
J, unpublished data personal report, 2009).
The quantitative study of the proposed structural glycocalyx
model [51] has shown that a high ﬂexural rigidity of the
ﬁbers on the cell surface is provided by the support of
the rigid actin ﬁlaments of the cortical cytoskeleton in the
transmembrane complexes of the core glycocalyx proteins
[54]. As a result, the submembrane “roots” of the glycocalyx
“bushes”areholdingﬁrmlythe“branches”oftheirﬁberclus-
ters (Figure 2). The long arm of the lever formed by the core
glycoproteins on the outside of the cell provides signiﬁcant
mechanical advantages inside the cell in terms of increasing
the ﬂux forces, exerted on the glycocalyx, in transferring
the interaction to the cortical cytoskeleton. Small ﬂux forces
acting ontheglycocalyxareampliﬁed bya suﬃcientintracel-
lular lever, capable of deforming the cortical cytoskeleton. It
is assumed that such mechanotransduction is the ﬁrst step in
the activation chain of intracellular signaling [54]. Hyaluro-
nan, a component of the glycocalyx, can interact with the
cytoskeleton through CD44 and RHAMM, the hyaladherins
associated with the glycocalyx [55]. RHAMM is associated
with the microtubules (of the mitotic cells), around which
the internalized hyaluronan is distributed [56, 57]. The
microtubules are an element in the development of the
cytoskeleton pressure for regulating cellular junctions and
cell shapes [58]. In this connection, it should be mentioned
that the appearance of cilia and ﬂagella on the endothelial
surface, formed by the centrosomal centrioles and assem-
bled from the microtubules, results in the development of
endothelial dysfunction in the areas of high-risk circulation
(with an oscillating shear stress) [59]. Moreover, endothelial
cilia can serve as regulators of the calcium signaling and NO
production via polycystin-1 [60, 61]. Enzyme destruction
of EG (treatment with heparinase, hyaluronidase, neu-
raminidase, excluding chondroitinase) completely blocked
shear-induced NO production by endothelial cells [62, 63].
None of these enzymes aﬀected bradykinin- or histamine-
induced NO production, indicating the multeity of NO pro-
duction machinery. Meanwhile, it conjectures the glycocalyx
may be organized into two layers: an inner region of several
tens of nm near the apical membrane surface and an outer
layer up to 0.5μm thick, which contains the extended core
proteins [64]. Between these layers may be located hyaluro-
nan. Heparansulfate seems to locate in outer layer due to
its prevailing content among glycocalyx glycosaminoglycans
[34] and observable role in mechanotransduction of shear
stress into endothelial cells for NO production (Figure 2)
[65]. Under physiological conditions, EG has several well
deﬁned functions aimed at preserving the integrity of the
vessel wall: inert barrier, molecular sieve, reservoir for bio-
logically active compounds, mechanotransductor transfer-
ring shear stress into shear-dependent endothelial responses
[64]. As a whole, according to the “double barrier concept,”
vascular barrier function is provided by two important
components, the endothelial glycocalyx and the endothelial
cells themselves [40, 43]. It can be hypothesized that extra-
cellular stimuli are conveyed to the cytoskeleton through the
structure of the glycocalyx, and then the endothelial cell uses
the cytoskeleton to develop a response, which can result, for
instance, in a change of cell shape or an initiation of new
events that alter the cellular functions.
7.Glycocalyx Degradation and Its Fragments in
Blood Circulation
The degradation of EG due to the development of vascu-
lar lesions leads to the release of its fragments into the
circulation. These fragments are currently believed to be
glycosaminoglycans, previously attached to the proteins on
the endothelial surface. The molecular size of hyaluronan
far exceeds the sizes of other glycocalyx glycosaminoglycans.
The hyaluronan molecule can be as long as 2.0–2.5μm[ 55].
The eﬀects associated with the formation of the hyaluronan
fragments have already been discussed in the literature [55,
66, 67]. There is a mounting body of data showing diﬀerent
types of biological activity of the hyaluronan fragments,
depending on their molecular weight [29]. The full-size
forms of hyaluronan have proved to have anti-inﬂammatory
and anti-angiogenic properties, the oligomers of 4–50 disac-
charides have angiogenic and pro-inﬂammatory properties
and stimulate tumor invasions, whereas the fragments of
3–12 and 6-7 hyalurononic polymeric moieties were found
to suppress tumor growth [66, 67]. The degradation of
hyaluronanisimportantforthefunctioningofthecapillaries
because hyaluronan regulates their permeability and the
junctions between endothelial cells [30, 68]. Hyaluronan
fragments are released in the circulation due to biochemical
degradation of the glycocalyx, de novo synthesis, and the
eﬀect of the oxidative stress [29, 67]. Inﬂammatory processes
caused by the oxidative fragmentation of hyaluronan, were
inhibited by the extracellular superoxide dismutase [69].
The exogenous hyaluronan fragments, from decasaccharides
upward, displace hyaluronan from the cell surface, whereas6 Biochemistry Research International
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Figure 2: Schematic representation of the glycocalyx meshwork associated with cytoskeleton. Hyaluronan weaves into glycocalyx and binds
with hyaladherins (CD-44 (hyalreceptor), RHAMM (receptor for hyaluronan-mediated motility), other proteins, or hyaluronansynthases).
Chondroitin sulfate proteoglycan (versican) interacts with hyaluronan to form high molecular mass stable aggregates. Enhanced formation
of hyaluronan-versican pericellular coat is observed under pathophysiological conditions (inﬂammation, early atherosclerosis, restenosis,
plaque thrombosis, and others).
the chondroitinsulfate does not have such eﬀect [70]. The
splitting of CD44 was caused by the small fragments of
hyaluronan (6.9kDa and other fragments with molecular
weight less than 36kDa), which in turn led to the increase
of tumor cell mobility due to detachment/dissociation of
thesecellsfromthetumor[71].Hyaluronanoligosaccharides
(composed of 4–16 saccharides) inhibit neointima growth in
the area of the rat aorta aﬀected by balloon catheterization
[72].Thismakessuchhyaluronanfragmentspotentialagents
for preventing restenoses following the angioplasty, because
theirformationiscausedpredominantlybythegrowthofthe
extracellularmatrix,ratherthanbycellproliferation[55,73].
Hyaluronicacidwasproposedtobeusedasthromboresistant
coating of the stents and endovascular devices [74].
Heparin, known for its anticoagulative properties, can
interact with ﬁbronectin, a protein of the extracellular
matrix, thereby triggering the transformation of its molecule
on the cell surface from closed to open conformation
[75]. The binding of heparin to the open conformation
is weakened, heparin dissociates from the protein, and
the binding centers of vascular endothelium growth factor
become exposed on the open conformation. Heparin, for
instance, can regulate the functions of extracellular matrix.
The enzymatic destruction of glycocalyx is accom-
plished by neuraminidase, chondroitinase, heparinase,
hyaluronidase,andotherbiocatalysts[26,46,50,55,67].The
treatment with mammal hyaluronidase results in the forma-
tion of oligosaccharides with an even number of polymeric
moieties that have N-acetylglucosamine at the reducing
end of the fragment [67, 76] .S u c hd e r i v a t i v e sg i v er i s et o
glycating agents [77]. The glycation of biomacromolecules,
especially in carbohydrate disorders, results in formation of
Amadori end-products, whose accumulation in the body
tissuesfacilitatesthedevelopmentofmetabolicdisorders,the
increaseinrigidityofthevascularwall,andproductionofthe
reactive oxygen species [77–80]. The interaction of Amadori
end-products (advanced glycation end-products) with their
corresponding receptors can facilitate these processes, by
aﬀecting the energetics of myocardial metabolism, its func-
tion, and by contributing to the myocardial damage after
ischemia/reperfusion [81]. In order to achieve therapeutic
eﬀect, the formation of Amadori end-products should be
blocked and a soluble form of the receptor should be used
[82].
The glycosaminoglycan biosynthesis comprises several
steps. The glycosaminoglycan chain initiation is catalyzed
by xylosyltransferase-1/2 that transfers xylose residues to a
certain serine in the core protein. This is the ﬁrst step in the
assembly of the linkage tetrasaccharide GlcAβ(1–3)Galβ(1–
3)Galβ(1–4)Xylβ(1-O-Ser)linkingtheproteinandthefuture
glycosaminoglycan chain. Galactosyl transferase-1 and -2,
and glucuronyl transferase-1 complete the assembly of the
linkagetetrasaccharidebyaconsecutivetransferoftwogalac-
tose residues and one residue of glucuronic acid. The subse-
quentelongationofthechainisaccomplishedbyanalternate
additionofthetransferredunitsofD-glucuronicacidandN-
acetyl-D-glucosamine to the tetrasaccharide. The ﬁnal step
in the synthesis of proteoglycans is associated with highly
coordinated multiple sulfation and epimerization of the gly-
cosaminoglycan. The biological signiﬁcance of glycosamino-
glycans is studied by exposing them to various agents
in the course of the glycosaminoglycan biosynthesis. The
following substances can serve as agents that change the gly-
cosaminoglycan biosynthesis: sodium chlorate, a bleachingBiochemistry Research International 7
agent, and brefedlin A, a fungal metabolite. Unfortunately,
these agents turned out to be highly lethal for the animal
m o d e l s .T h em o d i ﬁ e da n a l o g u e so fx y l o s ew e r ep r o v e dt o
be more suitable for studying [83]. These studies of xylose
analogues are currently underway and they can help to
examine the biological role of glycosaminoglycan derivates,
synthesized de novo in the organism.
8. Present Methods for Glycocalyx Study
In order to evaluate glycocalyx state, various methods
employing reporter agents (isotopes, labeled erythrocytes,
dextran) and novel research equipment (laser doppler
ﬂowmetry, positron emission, single-photon computerized,
magnetic resonance (using gadolinium, iron oxide) tomog-
raphy or their combinations) are used [14, 84, 85]. There
are ongoing studies looking for correlations between the
endothelial glycocalyx thickness in the microcirculation and
the risk factors for cardiovascular disorders. The novel
microcirculation imaging methods that proved eﬀective
during the studies with human volunteers are now being
developed: orthogonal polarization spectral imaging (OPS,
measured in the sublingual area) [86] and sidestream dark
ﬁeld imaging (SDF, measured on the nail fold) [14]. Cardio-
vascular magnetic resonance imaging of myocardial edema
detects acute ischemic myocyte injury before the onset of
irreversible damage [87]. This imaging may be a useful diag-
nosticmarkerinclinicalsettings(unstableanginaorevolving
infarction). The integration of the imaging techniques with
glycocalyx degradation products in plasma will conduce in
elicitation of EG role for cardiovascular risk stratiﬁcation.
EG is present in macro- as well as microvasculature and its
thickness progresses with increasing vascular diameter [34].
In larger vessel, the two-photon laser scanning microscopy
is suitable technique to visualize the delicate EG [88, 89].
The glycocalyx is thought to be a similarity in capillaries and
large vessel throughout the whole body [42]. It is not strange
therefore that arterial glycocalyx dysfunction could consider
the ﬁrst step in atherothrombosis process [90]. Glycocalyx is
implicated also in development of diabetes, atherosclerosis,
and ischemia/reperfusion injury [36]. The predicting the
future is ungrateful job but further research of EG looks
like the hopeful and breakthrough investigation in order to
decrease the spread of cardiovascular diseases.
9. Conclusion andPerspective
The progress in reperfusion therapy leads to the necessity
of developing new tools for adjacent treatment of cardio-
vascular disorders. One of the purposes of this treatment is
the damages of the microcirculation in acute coronary syn-
drome. The unfavorable prognosis for the patients without
“optimal” reperfusion places them in the high risk groups
that have the no-reﬂow phenomenon in microcirculation.
The clinical signiﬁcance of successful treatment of this
disorder oﬀers a new challenge in treating the patients with
AMI associated with ST-segment elevation. The studies of
the no-reﬂow phenomenon reveal various causes for its
development, paying, however, clearly insuﬃcient attention
to the role of EG. The study of the glycocalyx demonstrates
that this spatial meshwork structure provides a protective
function for the cell surface and that glycocalyx is capable to
serve as a molecular ﬁlter and hydrodynamic partner in the
interaction with cells and blood components. The action of
chemical (enzymes, reactive oxygen species, changes of the
medium pH value) and physical (shear stress, temperature,
ultrasound,photo-andradio-emission,etc.)factorschanges
the structure of the glycocalyx, which is currently intensively
studied and can inﬂuence the extent of the tissue perfusion.
A diverse biological activity of EG fragments is also clearly
evident and can substantially diﬀer, depending on the
molecular weight of these fragments. It is assumed that
the glycocalyx, being connected to the cytoskeleton, serves
as a mechanochemical transducer of the eﬀect that blood
circulation has on the processes of cell signaling. This may
suggest a predictive role for the state of glycocalyx in the
microcirculation. The path leading to our understanding
of the mechanism for these eﬀects is a very diﬃcult way.
However, an intention of following this path is justiﬁed by
the prospective of successful treatment in the patients with
complicated cardiovascular disorders.
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